Sonnet biotherapeutics announces updated clinical data for son-1010 at the 2023 american association for cancer research (aacr) annual meeting

Princeton, nj / accesswire / april 18, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of son-1010 dosing has been formally reviewed in both of the current phase 1 clinical trials, and the company is now enrolling the final dose cohort in the cancer trial. son-1010 is a proprietary version of human interleukin-12 (il-12), configured using sonnet's fully human albumin binding (fhab®) platform.
SONN Ratings Summary
SONN Quant Ranking